Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients
The Phase 3 MagnetisMM-5 trial demonstrated a statistically significant improvement in progression-free survival for ELREXFIO in patients with relapsed or refractory multiple myeloma compared to standard-of-care.